GlassScriptPhysician profile
Amanda J Phelps
NPI 1104101047
$3,668.50
in general payments reported to CMS, 2019-2025
43 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 96% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $211 · 2023: $531 · 2024: $1,461 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,057.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $411.49 | 2023-2025 | Otezla, Evenity, Repatha |
| Novo Nordisk INC | $362.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $360.00 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $275.68 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $260.41 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sumitomo Pharma America, INC. | $201.00 | 2023-2024 | Gemtesa |
| Lilly USA, LLC | $178.47 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.30 | 2023-2025 | Caplyta |
| Abbvie INC. | $167.07 | 2023-2025 | |
| Urovant Sciences INC | $114.98 | 2021-2022 | |
| Axsome Therapeutics, INC. | $105.34 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $96.94 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Alnylam Pharmaceuticals INC. | $82.92 | 2024 | Onpattro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.62 | 2023-2025 | Xifaxan, Trulance |
| Pfizer INC. | $65.33 | 2021-2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.